Alzheimer S Disease Equipment
-
Manufactured by BioArctic ABbased in SWEDEN
AD1503 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
-
Manufactured by BioArctic ABbased in SWEDEN
AD1502 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
-
Manufactured by BioArctic ABbased in SWEDEN
AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting Apolipoprotein E (ApoE), a different molecule than those targeted in the projects BAN2401 and BAN2401 ...
-
Manufactured by BioArctic ABbased in SWEDEN
In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. Lecanemab, a anti amyloid-beta protofibril antibody, selectively binds to these forms of amyloid beta and eliminates them. The antibody’s unique profile is highly selective for amyloid beta ...
-
Manufactured by Vitruvian BioMedical, Inc.based in USA
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the ...
-
Manufactured by C2N Diagnosticsbased in USA
The PrecivityAD® Blood Test Answers Calls from Patients, Advocates, and Healthcare Providers Who Want Earlier Answers. Summary of Test and Patient Selection. The PrecivityAD® test identifies whether a patient is likely to have the presence or absence of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s ...
-
Manufactured by Provista Diagnosticsbased in USA
The Lymphocyte Proliferation (LymPro) Test™ measures the immune proliferative response of white blood cells to mitogenic stimulation. Based on differences observed in the response of cells from patients with Alzheimer’s disease as compared with age-matched controls and patients with other dementias, it appears that the test has ...
-
Manufactured by BioArctic ABbased in SWEDEN
BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease. Our mission is to improve quality of life for patients suffering from Central Nervous System (CNS) disorders. Patients with ...
-
Manufactured by ViewPoint Behavior Technologybased in FRANCE
Analyzing an alert sign of Alzheimer’s disease, disorientation in familiar surroundings, in nontransgenic and transgenic mouse ...
-
based in USA
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and ...
-
Manufactured by C2N Diagnosticsbased in USA
The PrecivityAD2™ blood test is intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia, who are undergoing evaluation for Alzheimer’s disease or other causes of cognitive decline. A multi-analyte clinical diagnostic tool developed by C2N Diagnostics, the PrecivityAD2™ blood ...
-
Manufactured by BioArctic ABbased in SWEDEN
At BioArctic, research is in progress to develop new antibodies for the treatment of Alzheimer’s disease aimed at slowing down or stopping disease progression by addressing novel ...
-
Manufactured by C2N Diagnosticsbased in USA
The PrecivityAD® test measures the concentrations of amyloid beta 42 and 40 (Aβ42 and Aβ40), as well as the presence of Apolipoprotein E (ApoE) isoforms in the blood. The test indicates if an individual is likely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. ApoE4 genotype is a significant ...
-
Manufactured by Alzinova ABbased in SWEDEN
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. A first-in-human study in patients with early Alzheimer’s disease was initiated during third quarter of ...
-
Manufactured by C2N Diagnosticsbased in USA
The PrecivityAD™ test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help physicians better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s ...
-
Manufactured by Cirtec Medicalbased in USA
Signaling a Better Life: Neuromodulation devices are changing the game for treatment of spinal pain, hearing and vision loss, as well as stroke rehabilitation and tremor management. Further research is targeting treatment of Alzheimer’s disease, sleep disorders, arthritis and other chronic ...
-
Manufactured by SOFIEbased in USA
Neuraceq is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. ...
-
Manufactured by ReGen Therapeutics Limitedbased in UNITED KINGDOM
ReGen Therapeutics was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s ...
-
Manufactured by BioXcel Therapeutics, Inc.based in USA
BXCL501 is our most advanced neuroscience clinical program. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist. It is being investigated for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for agitation in Alzheimer’s ...
-
Manufactured by Woolsey Pharmaceuticals, Inc.based in USA
in Alzheimer’s ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you